![Sai Reddy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sai Reddy
Oprichter bij
Engimmune Therapeutics AG
Profiel
Sai Reddy is the founder of Engimmune Therapeutics AG, founded in 2021, holding the title of Director since 2021.
Dr. Reddy currently holds the positions of Chairman at deepCDR Biologics AG and Venture Partner at Pureos Partners AG.
Dr. Reddy completed a doctorate degree at École Polytechnique Fédérale de Lausanne in 2008 and an undergraduate degree at Northwestern University in 2003.
Actieve functies van Sai Reddy
| Bedrijven | Functie | Begin |
|---|---|---|
deepCDR Biologics AG
 deepCDR Biologics AG Miscellaneous Commercial ServicesCommercial Services Develops biotechnologies | Voorzitter | - |
Engimmune Therapeutics AG
 Engimmune Therapeutics AG BiotechnologyHealth Technology Develops drugs to treat tumor cancers | Oprichter | 01-01-2021 |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Private Equity Investor | - |
Opleiding van Sai Reddy
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
100
+
Eerstegraads connecties
5
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
École Polytechnique Fédérale de Lausanne
 École Polytechnique Fédérale de Lausanne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northwestern University
 Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners invests in companies located in Switzerland. The firm focuses on drug development companies. It participates in early stage capital transactions. | Finance |
deepCDR Biologics AG
deepCDR Biologics AG Miscellaneous Commercial ServicesCommercial Services Develops biotechnologies | Commercial Services |
Engimmune Therapeutics AG
Engimmune Therapeutics AG BiotechnologyHealth Technology Develops drugs to treat tumor cancers | Health Technology |
Kies MarketScreener 
